By collaborating with BoostFi, ArtGis brings advanced tools that improve customer experience, boost yields, and empower users to seize market momentum.By collaborating with BoostFi, ArtGis brings advanced tools that improve customer experience, boost yields, and empower users to seize market momentum.

ArtGis Finance Partners with BoostFi to Advance RWA Settlement and DeFi Asset Management Using AI-Powered Intelligence

nft-aii2 main

ArtGis Finance remains dedicated to staying ahead of the curve and leading the charge in innovation. Today, the decentralized trading platform announced a strategic collaboration with BoostFi, an AI-powered crypto platform, to elevate the DeFi experience on its network. Based on this partnership, ArtGis leverages BoostFi’s AI expertise to advance decentralized trading and liquidity provision, and eventually enhance the DeFi experience for its customers.

ArtGis Finance is a decentralized platform that uses blockchain technology and AI to revolutionize the cross-border movements of digital assets and real-world financial instruments. By connecting TradFi and Web3, ArtGis streamlines digital asset transaction/trading, financial settlements, and RWA liquidity. On the other hand, BoostFi is an intelligent platform that empowers cryptocurrency with AI. The multifaceted intelligent platform helps digital projects and clients understand and maximize their capabilities in the virtual currency landscape. The platform offers innovative intelligent tools for digital asset trading and investment management, enabling people to capitalize on cutting-edge AI features to maximize their trading potential and generate steady gains.

ArtGis Streamlining DeFi Asset Management Using BoostFi’s AI

By integrating BoostFi’s AI-driven trading capabilities into its decentralized trading ecosystem, ArtGis advances its platform’s capability, enabling it to deliver a more effective DeFi experience. While ArtGis’ DeFi platform provides an infrastructure for asset usage, trading, and lending, the integration of BoostFi’s AI agents helps personalize investment strategies, improve asset performance, and automate decision-making on ArtGis.

With the ability of BoostFi’s AI algorithms to analyze huge amounts of datasets and optimize DeFi strategies, these advanced capabilities help automate trading, improve liquidity management, and enhance yield generation on ArtGis. With continuous monitoring of market conditions, BoostFi’s agents ensure that tokenized assets on the ArtGis platform are deployed where they produce maximum profits with reduced risks. Also, BoostFi’s Al’s ability to analyze off-chain and on-chain data, assess risks, offer diverse portfolio rebalancing, and generate informed financial decisions enables ArtGis’ customers to maximize profits while decreasing exposure to volatility.

Finally, through BoostFi’s dynamic technology, ArtGis’ clients can access optimized trading experiences and profitability powered by AI insights that help project directional movements.

Developing the Effectiveness of DeFi 

The partnership between ArtGis and BoostFi sends a clear message that the future of decentralized finance lies in intelligent, customer-oriented platforms that focus on effectiveness, personalization, and safety. By infusing BoostFi’s AI expertise into its trading platform, ArtGis not only improves customer experience but also creates a new benchmark for what DeFi platforms can accomplish. The collaboration is a testimony to ArtGis’ dedication to innovation and its belief in the game-changing capability of blockchain and AI technologies.

Market Opportunity
Allo Logo
Allo Price(RWA)
$0.001939
$0.001939$0.001939
-2.12%
USD
Allo (RWA) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26